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Incretin-based therapies are widely used for type 2
diabetes and now also for obesity, but they are asso-
ciated with elevated plasma levels of pancreatic en-
zymes and perhaps a modestly increased risk of
acute pancreatitis. However, little is known about
the effects of the incretin hormone glucagon-like
peptide 1 (GLP-1) on the exocrine pancreas. Here,
we identify GLP-1 receptors on pancreatic acini
and analyze the impact of receptor activation in hu-
mans, rodents, isolated acini, and cell lines from
the exocrine pancreas. GLP-1 did not directly stimu-
late amylase or lipase release. However, we saw that
GLP-1 induces phosphorylation of the epidermal
growth factor receptor and activation of Foxo1, re-
sulting in cell growth with concomitant enzyme
release. Our work uncovers GLP-1-induced signaling
pathways in the exocrine pancreas and suggests that
increases in amylase and lipase levels in subjects
treatedwithGLP-1 receptor agonists reflect adaptive
growth rather than early-stage pancreatitis.INTRODUCTION
Glucagon-like peptide 1 (GLP-1) is a peptide hormone secreted
from the gastrointestinal tract in response to nutrient ingestion.
GLP-1 potentiates glucose-induced insulin secretion from
pancreatic b cells (the incretin effect) and suppresses appetite
and food intake (Holst, 2007). GLP-1 receptor agonists (GLP-
1RAs) are therefore used for the treatment of type 2 diabetes
and obesity (Wewer Albrechtsen et al., 2014; Drucker and Yusta,
2014; Sadry and Drucker, 2013). Their pancreatic safety has
been under intense debate (Meier and Nauck, 2014; ButlerCell Repor
This is an open access article under the CC BY-Net al., 2013; Elashoff et al., 2011; Egan et al., 2014), since their
use has been associated with sporadic cases of acute pancrea-
titis and generally mildly elevated levels of markers of this dis-
ease (amylase and lipase) in animal and clinical studies, although
the underlying mechanisms are unknown (Egan et al., 2014).
In the present study, we investigated the effects of GLP-1RAs
on the release of pancreatic amylase and lipase both in acinar
cell lines and in mice, rats, and humans, and as well the molec-
ular mechanism(s) leading to increased levels of pancreatic
enzymes.
RESULTS
The GLP-1 Receptor Is Expressed on Acinar Cells, and
Its Activation Stimulates cAMP Production
Autoradiography with an 125I-labeled GLP-1R antagonist, exen-
din 9-39 (EX9-39), revealed specific binding to pancreatic acinar
and b cells (Figures 1A and 1B). Binding was blocked by addition
of a 1,000-fold excess of unlabeled EX9-39, demonstrating
specificity of the binding. Using a well-characterized and vali-
dated GLP-1 receptor (GLP-1R) antibody (Pyke et al., 2014),
we demonstrated GLP-1R expression in pancreatic acinar cells
(positive staining for amylase), which was missing in tissue
biopsy specimens from GLP-1R knockout mice (Figure 1C). A
commercially available GLP-1R antibody (Figure S1A) showed
similar results. Subsequently, we showed expression of GLP-
1R in two acinar cell lines and isolated acini, both at the protein
level (using the validated GLP-1R antibody) and as messenger
transcript, similar to the expression seen in INS1 and GLP-1R
transfected HEK293 cells (Figure 1D). Both native GLP-1 and
EX4 (a GLP-1RA) stimulated production of cyclic AMP (cAMP)
dose dependently in two acinar cell lines and isolated acini (Fig-
ure 1E). Blocking the effects of GLP-1R stimulation, either by
administering the antagonist EX9-39 or by small interfering
RNA (siRNA)-induced knockdown of GLP-1R (80% and
74% knockdown for the CRL2151 and the AR42J cell lines,ts 17, 2845–2856, December 13, 2016 ª 2016 The Author(s). 2845
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2846 Cell Reports 17, 2845–2856, December 13, 2016
respectively, estimated by qPCR; Figure 1F), resulted in sig-
nificantly attenuated GLP-1- (p < 0.01) and EX4-induced
(p < 0.01) cAMP levels (Figure 1F). Appropriate controls,
including mock siRNA, GLP-1R siRNA, or EX9-39 alone, showed
no significant effect on the levels of cAMP (Figure 1F).
Acute Stimulation with Native GLP-1 or a Stable GLP-
1RA Stimulates Neither Amylase nor Lipase Levels in
Acinar Cell Lines or Mice, Rats, and Humans
The two cell lines (CRL2151 and AR42J) were further character-
ized by amylase and lipase expression at the transcript and
protein levels (Figures S1B and S1C) and tested functionally by
addition of 10 nM CCK-8, which resulted in a robust release of
amylase and lipase from both cell lines (5- to 20-fold,
p < 0.001; Figure 2A). GLP-1 and EX4, in doses ranging from 1
to 100 nM, neither stimulated nor inhibited amylase (p = 0.86)
or lipase (p = 0.75) activity levels in either of the two acinar cell
lines or isolated acinar cells (Figures 2B and S1D). Administration
of the stable GLP-1RA EX4 (10 nM) for 24 hr had no effect on pro-
tein levels of either amylase or lipase compared to PBS-treated
cells (Figure 2C). Addition of 1 nMGLP-1 to the arterial perfusate
of perfused mouse (p = 0.65, p = 0.31) and rat (p = 0.46, p = 0.47)
pancreata was also without effect on amylase and lipase release
(whereas in both species, insulin secretion was increased;
Figure 2D). In healthy subjects, subcutaneous injection of EX4,
GLP-1, or truncated GLP-1 (9-36NH2) had no acute effect
(120-min period) on plasma levels of amylase (p = 0.69,
p = 0.97, and p = 0.96, respectively) or lipase (p = 0.36,
p = 0.81, and p = 0.88, respectively) compared to placebo
(Figures 2E and 2F).
5-Day Treatment with GLP-1RA Increases Levels of
Pancreatic Enzymes and Cell Proliferation in Acinar Cell
Lines and in Isolated Acini
Administration of either 10 nM GLP-1 or 10 nM EX4 daily for
5 days increased activity levels (2-fold) of amylase (p < 0.001)
and lipase (p < 0.001) compared to PBS treatment in CRL2151
(Figures 3A and 3B) and AR42J (Figure S1E) cell lines, but not
in the HEK293 (control) cell line (p = 0.78) (Figure S1F). The stim-
ulatory effects of GLP-1 and EX4 on amylase and lipase levels
depended on GLP-1R expression, since the effect was reducedFigure 1. The GLP-1 Receptor Is Expressed on Acinar Cells, and GLP-
(A)Microphotographs (hematoxylin stained) of histological sections of a CD1mous
EX9-39 (negative control). The exocrine part of the pancreas is clearly labeled (mar
right field). Most of the isotope is localized to the basal layer of the secretory gland
the glands are only partially labeled. Note that most of the extracellular spaces b
(B)Microphotographs (H&E stained) of histological sections of a CD1mouse pancr
(negative control). The endocrine part (pancreatic islets) of the pancreas is clear
(C) Immunofluorescence using the extensively validated Mab 7F38 GLP-1R antib
mice illustrating the expression of GLP-1R on pancreatic acinar cells (also staine
(D) Detection of GLP-1R in both acinar cell lines and isolated acini by immunoflu
gene).
(E) cAMP production in the two cell lines, CRL2151 and AR42J, and isolated aci
(F) cAMP production in CRL2151 and AR42J cells after 1 hr of GLP-1 and EX4 stim
GLP-1R is inserted above each cell line) and EX9-39.
NC, negative control (PBS); PC, positive control. PC refers to overexpression of
represent statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001 by one-w
bars represent 10 mm (A and B) and 12 mm (C and D). n = 4–6 for biological repliby knockdown of GLP-1R (Figures 3A and 3B) (siRNA knock-
down efficiency 70% ± 7% for CRL2151 and 78% ± 5% for
AR42J cell lines, p < 0.01, estimated by qPCR; Figures 3A and
S2A). Of note, daily administration of 10 nM GLP-1 or 10 nM
EX4 stimulated proliferation of both acinar cell lines (2-fold,
p < 0.001) via a GLP-1R-dependent pathway, which was abol-
ished by both pharmacological (EX9-39) and genetic disruption
of GLP-1R (CRL2151 cell line (Figures 3C and 3D) and AR42J
cell line (Figures S2B and S2C; GLP-1R knockdown is depicted
in Figures 3A and S2A). The effect of GLP-1 and EX4 on cell
proliferation was similar with each method used to assess prolif-
eration: live-cell imaging (IncuCyte), nucleoside-based analog
(bromodeoxyuridine [BrdU]/5-ethynyl-20-deoxyuridine [EdU]),
and antibody staining-based (Ki-67) imaging (Figures 3C and
3D). GLP-1 or EX4 treatment had no effect on apoptosis in acinar
cells (CRl2151) compared to PBS (Figure S2D). In isolated acini
(from 4 mouse pancreases), amylase and lipase activity levels
increased after 5 days of EX4 administration concomitantly
with an EX-4 induced growth (1.8 ± 0.3-fold versus 1.1 ± 0.2-
fold, p = 0.03, assessed using the IncuCyte technique) (Fig-
ure 3E). The simultaneous administration of EX9-39 blocked
both the increases in amylase and lipase activity levels and cell
growth. Levels of pancreatic enzymes correlated significantly
with cell proliferation (amylase: R2 = 0.88; p < 0.0001 and lipase:
R2 = 0.47; p = 0.002) (Figure 3F).
7-Day Treatment with a GLP-1RA In Vivo Increases
Levels of Pancreatic Enzymes and Acinar Cell
Proliferation in Mice
Liraglutide, a long-acting GLP-1RA, significantly stimulated
amylase (37 ± 10 mU/mL versus 14 ± 3 mU/mL, p < 0.0001)
and lipase (9 ± 2mU/mL versus 3 ± 2mU/mL, p < 0.0001) activity
levels in plasma of mice compared to PBS treatment (Figures 4A
and 4B). Furthermore, liraglutide also significantly increased
pancreas weight (8.9 ± 0.9 mg/g mouse versus 7.1 ± 0.5mg/g
mouse, p = 0.0007; Figure 4C), although decreases in body
weight were not significant (5.7 ± 1.8 g versus 3.6 ± 1.2 g,
p = 0.20) compared to PBS-treatedmice. Liraglutide significantly
increased proliferation of acinar cells compared to PBS treat-
ment, both when cell proliferation was estimated by nucleo-
side-based analog (EdU) (3.0% ± 1% versus 0.7% ± 0.4%1 Receptor Activation Stimulates cAMP Production In Vitro
e pancreas using 125I-labeled EX9-39 without (top) andwith (bottom) unlabeled
ked bywhite arrows; the area pointed to by the red arrow ismagnified in the top
cells, whereas the apical part of the cells seems nearly unlabeled. The lumina of
etween the exocrine glands are free of iodinated particles.
eas using 125I-labeled EX9-39 without (top) andwith (bottom) unlabeled EX9-39
ly labeled.
ody of pancreatic tissue biopsy specimens from mice and GLP-1R knockout
d for amylase, depicted as red).
orescence (using Mab 7F38) and qPCR relative to the RPLP0 (housekeeping
ni after 1 hr of GLP-1 and EX4 stimulation.
ulation and simultaneous blockade of GLP-1R by siRNA (relative knockdown of
GLP-1R in (D) and 1mM IBMX, forskolin, and bombesin in (E) and (F). Asterisks
ay ANOVA corrected by a post hoc analysis [Sidak] for multiple testing). Scale
cates; n = 2–3 for technical replicates. Values represent mean ± SEM.
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Figure 2. Acute Administration of GLP-1 Stimulates Neither Amylase nor Lipase Activity in Acinar Cells, Acinar Cell Lines, or Mice, Rats, and
Healthy Subjects
(A) Amylase activity levels (top) and lipase activity levels (bottom) during PBS and CCK-8 (1 nM) stimulation of CRL2151, AR42J, and HEK293 cells (1 hr).
(B) Amylase activity levels (top) and lipase activity levels (bottom) during GLP-1 stimulation in CRL2151, AR42J, and isolated acinar cells (1 hr).
(C) Western blot profile after 24-hr incubation of CRL2151 cells with EX4 (10 nM) or PBS. From top: lipase, amylase, and control (actin).
(D) Amylase and lipase activity levels in the effluents from perfused pancreases frommice (top) and rats (bottom) during 1 nMGLP-1 administration. Insulin levels
were used as a positive control for GLP-1 stimulation.
(legend continued on next page)
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EdU positive cells, p < 0.0001) (Figure 4D) and by Ki-67 staining
(3.1% ± 0.8% versus 0.5% ± 0.3% Ki-67 positive cells,
p < 0.0001) (Figure 4E). Notably, the distribution of EdU- and
Ki-67 positive cells was independent of their spatial relationship
to neighboring islets (20 ± 10 versus 3 ± 5 EdU/Ki67-positive
cells by a 150 mm ratio to insulin-positive cells, p = 0.009) (Fig-
ure S2E), suggesting that proliferation may not necessarily be
related to a GLP-1-stimulated release of insulin. There was no
difference in number of EdU-positive islets between the groups
(Figure S2F) and no significant changes in total DNA content of
the pancreases, but a small and significant (p = 0.0045) increase
in protein content was found (Figure 4F). Biopsy specimens from
the gastrointestinal tract served as positive controls for cell
growth (Figure S3A). Plasma levels of insulin were slightly higher
after liraglutide compared to PBS treatment, but this did
not reach statistical significance (liraglutide-treated mice, 0.6 ±
0.1 ng/mL; PBS-treated mice, 0.4 ± 0.1 ng/mL; p = 0.12; data
not shown).
GLP-1-Induced Proliferation of Acinar Cells Is Mediated
by Translocation of c-Src and Subsequent
Phosphorylation of Epidermal Growth Factor Receptor
None of the three cAMP/IP-3 downstream signaling pathways
(protein kinase A [PKA], protein kinase C [PKC] and ‘‘exchange
protein directly activated by cAMP 2’’ [Epac2]) were necessary
for GLP-1 stimulation of acinar cell proliferation, as specific
inhibitors of PKA (KT5720), PKC (calphostin), and Epac2
(HJC 0350) had no effect on GLP-1-induced cell proliferation
(Figure 5A).
We therefore tested whether GLP-1-induced cell prolifera-
tion was mediated by c-Src/EGFR related pathways (c-Src,
epidermal growth factor receptor [EGFR], phosphatidylinositol
3-kinase [PI3K], and Foxo1), as reported for pancreatic b cells
(Buteau et al., 2006). Selective inhibitors of c-Src (PP1,
p < 0.001), EGFR (erlotinib and tyrphostin AG 1478, p < 0.01),
PI3K (LY294002, p < 0.01), and Foxo1 (AS1842856, p = 0.079)
all attenuated GLP-1RA-induced cell proliferation compared to
cells treated with only EX4 or inhibitor alone (Figure 5B). GLP-
1-induced phosphorylation of the downstream signaling protein
Akt was blocked (p < 0.01) by EX9-39; phosphorylation of
Akt was also blocked by the inhibition of c-Src, EGFR, and
PI3K (Figures S3B and S3C).
To further investigate how GLP-1R leads to c-Src activation,
we stained cells using anti-c-Src and c-Src phosphorylation
(Tyr416) antibodies during treatment with 50 nM GLP-1 or
vehicle. These experiments (Figure 5C) showed that GLP-1R
activation mediates phosphorylation of c-Src and subse-
quently redistributes c-Src from the perinuclear areas to the
cell borders. GLP-1 (p = 0.009) increased the phosphorylation
of the Foxo1 molecule, which subsequently resulted in a redis-(E and F) GLP-1 (red circle), GLP-1 9-36NH2 (blue circle), and EX4 (green square) a
amylase (E) activity (p = 0.69, p = 0.97, and p = 0.96, respectively) or lipase (F) a
placebo (black circle).
Data are shown as mean ± SD, and total area under the curve (tAUC) (E and F) are
maximum value). NC, negative control (PBS); PC, positive control (100 nM CCK-8
and ****p < 0.0001 by one-way ANOVA corrected by a post hoc analysis [Sida
replicates. Values represent mean ± SEM.tribution of Foxo1 from the nucleus to the cytoplasm
(Figure 5D).
DISCUSSION
Here, we demonstrate that acute administration of GLP-1 or
GLP-1RAs has no effect on the release of the exocrine pancre-
aticmarkers lipase and amylase in acinar cell lines, isolated acini,
or mice, rats, and healthy human subjects. In contrast, longer-
term (4–7 days) treatment of two acinar cell lines, isolated acini,
and mice in vivo increased basal secretory rates of amylase and
lipase. This was associated with a concomitant proliferation of
the acinar cells, which appeared to be coupled to redistribution
of c-Src, resulting in phosphorylation of EGFR and activation of
its downstream signaling pathways, including the Foxo1 system.
Our data thus provide a mechanistic explanation for the
elevated pancreatic enzyme levels in humans treated with
GLP-1RA, which differs from the interpretation by others of the
increases as being early signs of subclinical pancreatitis (Butler
et al., 2013). Our findings are consistent with the recently pub-
lished joint statement (Egan et al., 2014) by the US Food and
Drug Administration (FDA) and the European Medicines Agency
(EMA), who, after considering all available animal (18,000 ani-
mals) and clinical data (41,000 participants, including 28,000
exposed to GLP-1 [incretin]-based drugs), concluded that
although incretin-based drugs may increase amylase and lipase
levels (usually within normal ranges), a coupling to acute
pancreatitis could not be established. The absence of a clear
relationship is supported by large-scale randomized studies
with liraglutide (most recently by the LEADER study) (Pi-Sunyer
et al., 2015; Davies et al., 2015; Marso et al., 2016) published
after the FDA/EMA report, as well as other large cardiovascular
safety outcome studies with GLP-1 receptor agonists (lixisena-
tide) and DPP-4 inhibitors (which elevate levels of endogenous
GLP-1), all showing non-significant changes in acute pancrea-
titis rates as compared to placebo treatment control groups,
albeit with a numerical imbalance in some studies (Scirica
et al., 2013; White et al., 2013; Green et al., 2015; Bentley-Lewis
et al., 2015). Similar findings were made with liraglutide in a large
study in obese nondiabetic individuals, although again, a non-
significant imbalance between placebo and liraglutide was noted
(Pi-Sunyer et al., 2015). These data do not exclude an associa-
tion with acute pancreatitis but indicate that this complication
must be very rare. However, an explanation for the elevated
levels of lipase and amylase could not be provided in these
studies.
In our acute studies in humans, we used a therapeutic dose of
a stable GLP-1RA (exenatide; 10 mg), as well as a large subcu-
taneous dose of native GLP-1 to provide an acute, but therapeu-
tically relevant and relatively long-lasting (given short survival ofdministered to eight healthy subjects did not significantly increase the levels of
ctivity (p = 0.36, p = 0.81, and p = 0.88, respectively) in plasma compared to
shown as boxplots with 25, 50, and 75 percentiles and whiskers (minimum and
). Asterisks represent statistical significance (*p < 0.05, **p < 0.01, ***p < 0.001,
k] for multiple testing). n = 4–8 for biological replicates; n = 2–3 for technical
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Figure 3. GLP-1RA Increases Levels of Amylase and Lipase Concomitantly with Proliferation in CRL2151, AR42J, and Primary Acinar Cells
(A and B) Amylase and lipase levels in incubation media after daily administration of 10 nMGLP-1 (A) or 10 nM EX4 (B) for 5 days to CRL2151 cells with or without
GLP-1R siRNA. Relative GLP-1R expression is inserted above in (A).
(C and D) Cell proliferation estimated by IncuCyteZOOM, BrdU, or KI-67 after 5-day administration of 10 nM GLP-1 (C) or 10 nM EX4 (D) to CRL2151 cells with or
without EX9-39 or GLP-1R siRNA. Administration of EX9 or siRNA alone did not affect cell growth compared to PBS-treated cells.
(E) Amylase and lipase activity levels increased after 5-day daily EX4 administration with or without EX9-39 in primary acinar cells.
(F) Correlations between amylase (left) or lipase levels (right) with the proliferation index in CRL-2151.
Asterisks represent statistical significance (*p < 0.05, **p < 0.01, and ***p < 0.001 by one-way ANOVA corrected by a post hoc analysis [Sidak] for multiple testing.
n = 6–8 for biological replicates; n = 2–3 for technical replicates. Values represent mean ± SEM.
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Figure 4. Liraglutide Increases Levels of
Amylase and Lipase Concomitantly with
Proliferation in Mice
(A and B) Plasma levels of amylase (A) and lipase
activity (B) increase during 7-day treatment with
the GLP-1RA liraglutide in mice.
(C–E) Pancreas weight (C) and number of EdU-
and Ki-67-positive acinar cells (D) based on
staining of the corresponding pancreas tissue
(E) increased significantly in liraglutide-treated
mice (n = 8) compared to PBS-treated mice (n = 8).
In (E), cells were also stained for amylase protein
(red).
(F) Protein content (right) and DNA content (left)
from pancreas biopsy specimens from PBS-
treated and liraglutide-treated mice.
Asterisks represent statistical significance (*p <
0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001
by one-way ANOVA corrected by a post hoc
analysis [Sidak] for multiple testing). n = 8 for
biological replicates; n = 2–3 for technical repli-
cates. Scale bars represent 40 mm (E, left), 20 mm
(E, middle), and 15 mm (E, right). Values represent
mean ± SEM.intact GLP-1 in the circulation) and robust elevation of the
plasma concentrations. Moreover, since the predominant circu-
lating form of endogenous GLP-1 is the N-terminally truncated
product of DPP-4 action, GLP-1 9-36 NH2 (Deacon et al.,
1995), which may share some effects with GLP-1 (Ban et al.,
2008), we also examined the effects of this peptide at relevant
doses. The lack of acute effect on levels of pancreatic enzymes
is in agreement with data showing no effect of meal-induced in-
creases in endogenous GLP-1 in patients with type 2 diabetes
(Sonne et al., 2015). Similarly, there were no acute effects of
GLP-1 or GLP-1RAon pancreatic enzyme secretion in two acinar
cell lines, isolated acini, and perfused pancreases frommice and
rats. Hou et al. recently reported increased amylase activity in
the incubation medium of mouse acini isolated from wild-type,Cell Reportsbut not GLP-1R-deleted, mice (Hou
et al., 2016). In agreement with the orig-
inal studies by Raufmann and Eng (Singh
et al., 1994), there was also an increase in
cAMP, but the latter authors were unable
to demonstrate amylase release, and in
studies using isolated perfused pig pan-
creases, which secrete pancreatic juice
and enzymes at normal in vivo rates,
GLP-1 had no effects on enzyme secre-
tion (Holst et al., 1993), in agreement
with the observations presented here.
Moreover, the apical release of zymogen
granules from acinar cells is normally
not associated with increases in plasma
levels of the enzymes, the main focus
of the present studies, in spite of in-
creases in stimulatory hormones and in
plasma GLP-1. A very recent research
letter described initial decreases, lasting150 min, with extremely small (3–4 U/L) and late (2.5 hr after a
meal) increases in amylase (and no effect on lipase) in subjects
with type 2 diabetes after infusion of exendin 4, which, consid-
ering the powerful effects on upper gastrointestinal motility and
secretion, would be difficult to interpret in relation to pancreatic
secretion or release (Smits et al., 2016).
In contrast, longer-term (4–6 days) treatment of mice with
GLP-1RA was associated with increased basal levels of amylase
and lipase, which occurred in parallel with increases in the
mitosis rates of acinar cells. These results regarding GLP-1-
induced proliferation are consistent with other data obtained in
mice (Ellenbroek et al., 2013), rats (Perfetti et al., 2000; Gier
et al., 2012; Nachnani et al., 2010), and monkeys (Nyborg
et al., 2012). A more recent study suggested that GLP-1R17, 2845–2856, December 13, 2016 2851
Figure 5. GLP-1 Effect on Cell Proliferation Is Mediated by EGFR Signaling through Phosphatidylinositol 3-Kinase, Akt Phosphorylation, and
the Foxo1 System
(A) Inhibiting cAMP-related pathways had no effect on EX4-induced cell proliferation of the CRL2151 cell line.
(B) Specific inhibitors of c-Src (20 nM), EGFR (1 mg/mL), PI3K (1 m/mL), and foxo1 (50 nM) all resulted in attenuated EX4-induced cell proliferation.
(legend continued on next page)
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activation results in increased protein synthesis (and therefore
increased pancreatic mass) rather than cell proliferation (Koehler
et al., 2015). We could clearly show in vitro not only proliferation
but also its dependence on GLP-1R expression, suggesting a
direct effect of GLP-1 on acinar cells, as opposed to indirect
pathways involving, for instance, increased insulin secretion
from pancreatic b cells or, for the in vivo experiments, non-
pancreatic factors. Finally, we also provide mechanistic insight
on how GLP-1 and GLP-1RA might affect the acinar cells. Clas-
sical GLP-1R signaling (Gas) involves production of cAMP with
subsequent activation of PKA and the Epac family. However,
there is evidence that GLP-1R signaling in b cells may also
involve an EGFR-dependent activation of the Foxo1 system,
supporting b cell rejuvenation (Carter and Brunet, 2007; Hall
et al., 2000). Since little is known about GLP-1R signaling in
exocrine acinar cells, we investigated whether GLP-1-induced
proliferation was mediated through cAMP-mediated mecha-
nisms and found, to our surprise, that this was not the case.
Instead, we identified an intracellular mechanism for GLP-1R
signaling involving c-Src that eventually leads to activation of
EGFR. Indeed, c-Src and subsequent EGFR phosphorylation
were essential for GLP-1R signaling in acinar cells.
Collectively, our data demonstrate that GLP-1-induced in-
creases in amylase and lipase are dependent on c-Src signaling
and acinar cell growth. We included two acinar cell lines (CRL-
2151 and AR42J, the latter differentiated with steroids toward
an acinar phenotype; Logsdon et al., 1985) and isolated acini
(frommice) and demonstrated that GLP-1R activation eventually
leads to cell proliferation. The biological relevance of the in vitro
results was substantiated by the observations made after daily
injection for 7 days with the GLP-1RA liraglutide, which signifi-
cantly stimulated plasma levels of amylase and lipase in mice
concomitantly with proliferation of acinar (amylase-positive)
cells. This suggests that GLP-1 does not stimulate the release
of pancreatic enzymes per se but increases circulating levels
of these enzymes due to a growth-dependent increase of their
basal activities. The mild increase in proliferation appears to be
an acute adaptive response, which is fully in line with studies
showing no adverse histological changes or increases in pancre-
atic cancer (Ueberberg et al., 2016; Azoulay et al., 2016).
In summary, our findingssuggest that the elevatedamylaseand
lipase levels in GLP-1-treated subjects reflect adaptive growth of
pancreatic acinar cells rather than subclinical pancreatitis.
EXPERIMENTAL PROCEDURES
Human Experiments
Eight normoglycemic healthy subjects (three females and five males; age, 24 ±
3 years; weight, 71 ± 11 kg; BMI, 23 ± 1) were included in this double-blinded(C) GLP-1 phosphorylates and subsequently redistributes c-Src from perinuc
GLP-1 treated (48 hr). Left: anti-c-Src antibody (red) and anti-c-Src (green: p
magnification and merged with DAPI. White arrowheads point to localization o
phosphorylation of the c-Src molecule, and this subsequently leads to redist
panels.
(D) GLP-1 (incubation for 48 hr) increased phosphorylation of Foxo1 and increa
assess cell proliferation in the above mentioned panels. Asterisks represent statis
way ANOVA corrected by a post hoc analysis [Sidak] for multiple testing). n = 5–
Values represent mean ± SEM.crossover study. Subcutaneous injections of saline, GLP-1 7-36NH2
(1.5 nmol/kg), GLP-1 9-36NH2 (1.5 nmol/kg), or exendin-4 (EX-4; 10 mg)
were given at time zero on four different days with aminimum of 2-day intervals
within a total time period of 3 months, and blood samples were obtained
at15, 0, 15, 30, 45, 60, 90, and 120min. The study was conducted according
to the latest revision of the Helsinki Declaration and approved by the Scientific-
Ethical Committee of the Capital Region of Denmark and by the Danish Data
Protection Agency (application SJ-497). Written informed consent was
received from participants prior to inclusion in the study.
Animal Experiments
All animal experiments were approved by the Danish National Committee for
Animal Studies, Ministry of Justice (201315293400833) and were con-
ducted in accordance with the EU Directive 2010/63/EU and guidelines of
Danish legislation governing animal experimentation (1987) and the NIH (pub-
lication number 85-23) as previously described (Kuhre et al., 2014; Wewer
Albrechtsen et al., 2016).
In Vivo Animal Experiments
Female C57BL/6JRj mice (20 g; Janvier Labs) were housed eight per cage
under standard conditions for at least 2 weeks before experiments. Mice
were divided into weight-matched groups (each 22 ± 1 g) receiving two daily
(morning and evening) subcutaneous (s.c.) injections of liraglutide (Novo
Nordisk A/S) (0.2 mg/kg, 100 mL) or PBS (100 mL). Both groups also received
two daily s.c. injections of EdU (catalog number BCK488-IV-IM-M, Sigma-
Aldrich; 50 mg/kg, 200 mL) to assess cell proliferation. Seven days later, the
mice were anesthetized with an s.c. injection of ketamine (catalog number
511485, Ketaminol, Intervet, Merck, dose 100 mg/kg) and xylazine (catalog
number 148999 Rompun vet, Bayer AG, dose 10 mg/kg). The abdomen was
opened and a needle inserted into the caval vein. A maximal blood sample
was collected and transferred to an EDTA-coated tube (catalog number
367841, Becton, Dickinson and Company). The samples were centrifuged
(1,650 3 g, 4C, for 10min) and plasma was immediately frozen at 20C.
Pancreas tissue was harvested and fixed in 10% (w/v) formaldehyde in
0.1 M phosphate buffer (pH 7.4) for 24 hr at 4C. The tissue was then dehy-
drated in ethanol and xylol and finally embedded in paraffin wax. 3-mm-thick
paraffin sections were cut for immunohistochemistry and placed on Superfrost
Plus glass slides. Immediately after collection of the pancreatic tissue, the
animals were killed by exsanguination.
Cell Culture
HEK293-VnR cells were generated from HEK293 cells by stable overexpres-
sion of aVb3 integrin (Sanjay et al., 2001). TheCRL-2151 (266-6) acinar pancre-
atic cell line, derived from a mouse tumor induced with an elastase I/SV-40 T
antigen fusion gene (Ornitz et al., 1985), and the AR42J rat pancreatic tumor
cell line were both from ATCC. The AR42J cell line was differentiated toward
an acinar-like phenotype as described previously (Logsdon et al., 1985).
INS-1E cells were kindly provided by Professor Jens Højris Nielsen (University
of Copenhagen, Denmark). Isolation of murine acini was performed using a
well-established method described previously (Gout et al., 2013). In brief,
four murine pancreases were dissected and processed using the protocols
kindly provided by Gout et al., and the isolated acini were seeded in six-well
culture dishes (2 mL per well) and cultured at 37C under 5% (v/v) CO2 atmo-
sphere. Cells were grown in DMEM (catalog number 31966-021, Gibco)
containing 5,000 U/mL penicillin/streptomycin (catalog number 15140-122,
Gibco) and 10% fetal bovine serum (FBS) (catalog number Sv3016003,lear areas to cell borders in CRL-2151 cells. Top: control (PBS). Bottom:
hosphorylated Tyr416) antibody. Right: cells stained for c-Src with larger
f the c-Src of the cell membrane. The left panels show that GLP-1 induces
ribution of the c-Src molecule to the cell membrane as shown in the right
sed translocation of foxo1 out of the nuclei. The IncuCyteZOOM was used to
tical significance (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 by one-
7 for biological replicates; n = 2–3 for technical replicates. Scale bars, 12 mm.
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Thermo Fisher Scientific). The cells were seeded in 24-well plates (Nunc,
Thermo Fisher Scientific) at a cell density of 4 3 104 per well.
Ex Vivo Experiments
Isolated mouse and rat pancreases were perfused as described in Supple-
mental Experimental Procedures.
In Vitro Experiments
For acute stimulation protocols, we used 80% confluent cells from different
batch numbers (n = 3). Cells were stimulated with GLP-1, EX4, and EX9-39
(concentration range 1–1,000 nM) for up to 1 hr. In pilot studies, we included
stimulation periods of 5, 10, 30, and 60 min. For longer-term stimulation,
similar numbers of cells were placed in each well of 12-well plates; every sec-
ond hour (up to 120 hr), the cells were automatically counted using IncuCyte
Zoom equipment (Essen BioScience). In addition, BrdU (Click IT) was admin-
istered daily together with stimulants (GLP-1, EX4, EX9-39, or enzyme
inhibitors). After the end of the stimulation period, cell media were obtained
and centrifuged (1,500 3 g, 4C, 5 min) to remove any cells or debris and
kept at 80C until analysis.
Antibodies and Proteins
GLP-1R antibody (Monoclonal antibody [Mab] 7F38) was deposited to the
Developmental Studies Hybridoma Bank (DSHB) by Knudsen, L.B. (DSHB
Hybridoma Product Mab 7F38) and used for Figure 1. The peptides GLP-1
7-36NH2 (catalog number H-6795), GLP-1 9-36NH2 (catalog number
H-4012), exendin 9-39 (EX9-39; catalog number H-8740), exendin-4 (EX4;
catalog number H-3864), and sulfated cholecystokinin octapeptide (CCK-8;
catalog number H-2080) were all from Bachem. Other reagents are listed in
Supplemental Experimental Procedures.
Proliferation Assay
IncuCyte ZOOM (Essen BioScience) was used to analyze and estimate the pro-
liferationgradeof theculturedcells as previously described (Stewart et al., 2015;
Craveiroet al., 2013;Dombernowskyet al., 2015). For adetaileddescription, see
Supplemental Experimental Procedures. IncuCyte ZOOM phase images were
taken automatically every second hour, which made it possible to monitor
cellular growth,behavior, andmorphologyby live-cell imaging (label-freeconflu-
ence). In addition, the machine delivers an effective kinetic readout, i.e., graphs
showing proliferation for individual cell culture wells. Raw data (phase object
confluence and percentage) were used for illustrations without normalization.
Proliferation reflects the percentage increase of the phase object confluence
(percent). In parallel, two additional proliferation assays were performed using
theClick-iT EdUandBrdU imaging kits (catalog numberC10337, Invitrogen) ac-
cording to themanufacturer’s protocol. To estimate apoptosis, we used a color-
imetric TUNEL assay from Trevigen (catalog number 4822-96-K). For the in vivo
study, in addition to the EdU and staining by Ki67 (see below), we also assessed
protein andDNAcontent. In short, pancreas tissues (remaining pieces)were ho-
mogenized in a lysis buffer as describedby others (Koehler et al., 2015) and son-
icated for 1min. A standard biocinchoninic acid (BCA) protein assay fromSigma
(catalog number BCA-1) and a Quant-iT dsDNA assay from Thermo Fisher
Scientific (catalog number Q33120) were used.
qPCR and Small Interfering RNAs
For a detailed description, see Supplemental Experimental Procedures.
Immunohistochemistry, Immunofluorescence, and Autoradiography
Pancreatic acinar cell proliferation estimations were performed by acquiring
EdU/amylase/DAPI images of each section from the 16mice. Autoradiography
was performed using 125I-labeled EX9-39 as described previously (Jensen
et al., 2015).
Western Blot Analysis
For a detailed description, see Supplemental Experimental Procedures.
Biochemical Measurements
Pancreatic enzymeactivities, expressedasmU (mmol/min/mL),weremeasured
(blinded) using commercial colorimetric assays (amylase [ab102523] and lipase2854 Cell Reports 17, 2845–2856, December 13, 2016[ab102524], with lower limits of detection of 0.2 and 0.1 mU, respectively; both
from Abcam). For amylase and lipase activity in plasma samples, pancreatic
a-amylase and triacylglycerol lipase (pancreatic lipase) were measured on a
Cobas 8000 c502 platform (Roche Diagnostics GmbH) using Roche a amylase
EPS pancreatic reagents or Roche Lipase colorimetric assay, including
Calibrator f.a.s. For a detailed description, see Supplemental Experimental
Procedures.
Statistics
One-way ANOVA, corrected by a post hoc analysis (Sidak) for multiple testing,
was used for testing differences between more than two groups of data.
p < 0.05 was considered significant. For a detailed description, see Supple-
mental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.11.051.
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